Lisa Egbuonu-Davis, serving as a director at Phreesia, Inc. (NASDAQ: PHR), executed a sale of 536 shares in the company's common stock on July 14, 2026. The transaction, valued at $5,735, involved shares sold at a price of $10.70 each. As of the reporting period, Phreesia's stock is trading at $10.85. This current valuation sits significantly below the stock's 52-week high of $32.76, yet remains above its 52-week low of $7.77.
Following the completion of this transaction, Egbuonu-Davis maintains a direct holding of 37,780 shares of Phreesia common stock. The sale was conducted pursuant to a Rule 10b5-1 trading plan, which Egbuonu-Davis established on December 16, 2025. According to data from InvestingPro, Phreesia is currently viewed by analysts as potentially undervalued at its present price levels. Market analysts are forecasting that the company will achieve profitability within the current year. Further insights into the company's valuation can be accessed through comprehensive Pro Research Reports available for PHR and over 1,400 other US equities.
Recent corporate developments include Phreesia's first-quarter fiscal 2027 earnings report, which demonstrated performance exceeding market expectations. The company reported an earnings per share (EPS) of $0.05, a figure that notably surpassed the forecasted EPS of $0.01. Revenue also came in slightly above consensus estimates, with total revenue reaching $130.9 million against a predicted $130.1 million. Additionally, adjusted EBITDA was reported at $30.5 million, exceeding the expected $28.4 million.
Analyst reactions to these financial results have varied. Citizens maintained its Market Perform rating on Phreesia. DA Davidson reiterated a Buy rating, setting a price target of $14.00. In contrast, Piper Sandler downgraded Phreesia from Overweight to Neutral, adjusting its price target downward from $23 to $12, citing a shift in the company's profitability outlook. Truist Securities raised its price target on Phreesia to $12.00 from $11.00, while maintaining a Hold rating. Truist's revenue estimates for fiscal years 2027 and 2028 remain largely unchanged. These divergent analyst views reflect the mixed market reaction to Phreesia's financial performance and future outlook.